Frances K Heller - Net Worth and Insider Trading

Frances K Heller Net Worth

The estimated net worth of Frances K Heller is at least $38,007 dollars as of 2024-04-16. Frances K Heller is the EVP, Business Development of Exelixis Inc and owns about 1,500 shares of Exelixis Inc (EXEL) stock worth over $34,050. Frances K Heller is also the Director of Zafgen Inc and owns about 3,997 shares of Zafgen Inc (ZFGN) stock worth over $3,957. Details can be seen in Frances K Heller's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Frances K Heller has not made any transactions after 2017-10-13 and currently still holds the listed stock(s).

Transaction Summary of Frances K Heller

To

Frances K Heller Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Frances K Heller owns 4 companies in total, including Larimar Therapeutics Inc () , Bristol-Myers Squibb Co () , and Exelixis Inc () among others .

Click here to see the complete history of Frances K Heller’s form 4 insider trades.

Insider Ownership Summary of Frances K Heller

Ticker Comapny Transaction Date Type of Owner
Larimar Therapeutics Inc 2015-07-13 director
Bristol-Myers Squibb Co 2013-10-01 SVP & Business Development
Exelixis Inc 2009-11-02 EVP & Business Development
Monterey Innovation Acquisition Corp 2021-09-30 director

Frances K Heller Latest Holdings Summary

Frances K Heller currently owns a total of 2 stocks. Among these stocks, Frances K Heller owns 1,500 shares of Exelixis Inc (EXEL) as of November 2, 2009, with a value of $34,050 and a weighting of 89.59%. Frances K Heller also owns 3,997 shares of Zafgen Inc (ZFGN) as of October 13, 2017, with a value of $3,957 and a weighting of 10.41%.

Latest Holdings of Frances K Heller

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
EXEL Exelixis Inc 2009-11-02 1,500 22.70 34,050
ZFGN Zafgen Inc 2017-10-13 3,997 0.99 3,957

Holding Weightings of Frances K Heller


Frances K Heller Form 4 Trading Tracker

According to the SEC Form 4 filings, Frances K Heller has made a total of 0 transactions in Exelixis Inc (EXEL) over the past 5 years. The most-recent trade in Exelixis Inc is the sale of 2,529 shares on November 2, 2009, which brought Frances K Heller around $15,655.

According to the SEC Form 4 filings, Frances K Heller has made a total of 0 transactions in Zafgen Inc (ZFGN) over the past 5 years. The most-recent trade in Zafgen Inc is the acquisition of 833 shares on October 13, 2017, which cost Frances K Heller around $39,000.

Insider Trading History of Frances K Heller

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Frances K Heller Trading Performance

GuruFocus tracks the stock performance after each of Frances K Heller's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Frances K Heller is 26.88%. GuruFocus also compares Frances K Heller's trading performance to market benchmark return within the same time period. The performance of stocks bought by Frances K Heller within 3 months outperforms 4 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Frances K Heller's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Frances K Heller

Average Relative Return

46.21%

Average relative return per transaction

Outperforming Transactions

100%

4 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 2.13 26.88 37.85 46.21 31.11 -36.25
Relative Return to S&P 500(%) 0.78 21.78 31.08 31.66 21.46 -48.3

Frances K Heller Ownership Network

Ownership Network List of Frances K Heller

No Data

Ownership Network Relation of Frances K Heller


Frances K Heller Owned Company Details

What does Larimar Therapeutics Inc do?

Who are the key executives at Larimar Therapeutics Inc?

Frances K Heller is the director of Larimar Therapeutics Inc. Other key executives at Larimar Therapeutics Inc include 10 percent owner & other: Possible Member of 10% Group James E Flynn , Chief Development Officer Gopi Shankar , and Chief Medical Officer Russell Clayton .

Larimar Therapeutics Inc () Insider Trades Summary

Over the past 18 months, Frances K Heller made no insider transaction in Larimar Therapeutics Inc (). Other recent insider transactions involving Larimar Therapeutics Inc () include a net purchase of 4,290,617 shares made by James E Flynn , a net purchase of 5,000 shares made by Carole Ben-maimon , and a net purchase of 5,000 shares made by Gopi Shankar .

In summary, during the past 3 months, insiders sold 0 shares of Larimar Therapeutics Inc () in total and bought 4,292,617 shares, with a net purchase of 4,292,617 shares. During the past 18 months, 0 shares of Larimar Therapeutics Inc () were sold and 4,310,367 shares were bought by its insiders, resulting in a net purchase of 4,310,367 shares.

Larimar Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Larimar Therapeutics Inc Insider Transactions

No Available Data

Frances K Heller Mailing Address

Above is the net worth, insider trading, and ownership report for Frances K Heller. You might contact Frances K Heller via mailing address: 249 E. Grand Avenue, S. San Francisco Ca 94083.

Discussions on Frances K Heller

No discussions yet.